Tiziana Life Sciences announced that a study of the company’s intranasal anti-CD3 mAb will be funded by a $4 million grant from the National Institutes of Health. In June 2024, the company said that the FDA had approved the use of intranasal foralumab in a patient with moderate Alzheimer’s disease under an expanded access IND. Tiziana said that it anticipates initiation of Phase 1 trials of the nasal spray in Alzheimer’s patients within the next few months.
The nasal formulation of foralumab is also in Phase 2 development for the treatment of multiple sclerosis and recently received Fast Track designation for that indication. According to Tiziana’s web site, INDs are planned for intranasal foralumab for the treatment of long COVID and for the treatment of diabetes. The company has also announced plans to develop the nasal spray for the treatment of hemorrhagic stroke.
Tiziana Life Sciences CEO Ivor Elrifi commented, “We are thrilled to be able to progress our pipeline with this prestigious NIH grant, which underscores the potential of our anti-CD3 therapy to address a critical unmet need in Alzheimer’s disease. This funding will enable us to expand our research and move one step closer to developing a new therapeutic option for patients and families impacted by this debilitating condition. At Tiziana, we remain committed to advancing science that could improve the quality of life for patients through groundbreaking immunotherapies.”
Read the Tiziana Life Sciences press release.
